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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To assess the eFects of non-steroidal anti-inflammatory drugs (NSAIDs) for acute sore throat in children and adults.
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B A C K G R O U N D
Description of the condition
Acute sore throat, including pharyngitis and tonsillitis, is a very
common condition: the community incidence has been estimated
at 1.57 per person-year in a recent UK-based population-based
cohort study (Mehta 2017). With around 1 in 10 people seeking
medical care (Mehta 2017), sore throat is a common reason for
ambulatory care visits in high-income countries (Fleming-Dutra
2016; Gulliford 2014; Lewnard 2020). The condition can be of viral
or bacterial origin. The most prominent bacterium is group A
beta-haemolytic streptococcus (GAS), which is isolated in around
10% to 15% of adult and 15% to 30% of childhood cases in
Western countries (Bisno 2001; Hayward 2017; Linder 2005), but
epidemiology and severity may vary depending on geographical
location, with a GAS-positive rate of 42% reported in children with
sore throat living in a low-income setting (DeWyer 2020).
Irrespective of causative pathogen (i.e. whether viral or bacterial),
there is a need for symptom relief. High-quality evidence indicates
that antibiotics provide only marginal benefits in alleviating
symptoms in otherwise healthy people with uncomplicated
sore throat living in high-income countries (Spinks 2013), and
the number needed to treat to  prevent serious suppurative
complications such as peritonsillar abscess is estimated at over
4000 people in these countries (Petersen 2007). Nevertheless,
antibiotic prescribing  for people with this condition remains at
a high rate (Gulliford 2014; van den Broek d’Obrenan 2014).
Importantly, sore throat is amongst the conditions with the highest
antibiotic overprescribing rates (Dekker 2015; Fleming-Dutra 2016),
thereby exposing people to unnecessary side eFects (Gillies 2015),
and contributing to the emergence of antimicrobial resistance
(Costelloe 2010).
Description of the intervention
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit
prostaglandin synthesis by competitive binding to the
cyclooxygenase (COX) enzymes (COX-1 or COX-2, or both) and
can be divided into traditional (non-selective NSAIDs, which
inhibit the activity of both COX-1 and COX-2) and selective COX-2
inhibitors (Bruno 2014). COX-2 inhibition leads to reduced release of
pyrogenic molecules in the inflamed cells (mainly prostaglandin E2)
causing the anti-inflammatory, antipyretic, and analgesic eFects
of NSAIDs (Bruno 2014; Rainsford 2009). COX-1 inhibition is mainly
responsible for the gastrointestinal adverse eFects of NSAIDs
(Bruno 2014). NSAIDs, especially aspirin, also inhibit platelet
aggregation due to the inability of the COX enzyme to synthesise
thromboxane precursors within platelets.
A number of NSAIDs are on the market that are available over-
the-counter (OTC) in most countries. The most well-known NSAIDs
include aspirin, ibuprofen, diclofenac, and naproxen.
NSAIDs can be administered orally (suspension, tablets, capsules,
lozenges (partially locally)), locally (e.g. sprays into the throat),
rectally (suppositories), or by intramuscular or intravenous
injection.
How the intervention might work
Theoretically, both positive and negative eFects of NSAIDs used for
acute sore throat can be anticipated. Inflammation and subsequent
swelling of the oropharyngeal mucosa are thought to play a central
role in the occurrence and maintenance of the most prominent
symptoms of sore throat such as pain, diFiculties swallowing,
and ingesting food or drink. Reducing the host inflammatory
response may therefore alleviate symptoms and expedite recovery.
A recent Cochrane Review showed that corticosteroids in addition
to antibiotics increase the likelihood of both resolution and
improvement of pain in patients with sore throat (de Cassan
2020). The anti-inflammatory, antipyretic, and analgesic eFects
of NSAIDs could therefore also have a beneficial impact on sore
throat symptoms. Conversely, NSAIDs may have a negative impact
on the resolution of acute respiratory tract infections due to their
interference with human neutrophil functioning (Kaplan 1984),
which in turn might result in prolonged illness duration, an increase
in doctor reconsultations, and an enhanced risk of suppurative
complications including peritonsillar abscess (Basille 2017; Le
Bourgeois 2016; Little 2013; Little 2016; Nicollas 2020; Piroulas
2019; Voiriot 2011).
Why it is important to do this review
NSAIDs are available over the counter in many countries and
are commonly used to alleviate acute respiratory tract infection
symptoms including those associated with sore throat such as
pain and fever. However, their potential benefits for this condition
are unclear and have not been recently systematically reviewed
(Thomas 2000). Furthermore, any potential benefits should be
carefully balanced against the risk of side eFects. NSAIDs have
long since been associated with well-known side eFects such
as gastrointestinal bleeding, renal failure, and cardiovascular
diseases. More recently, observational and randomised controlled
trial evidence has become available indicating that NSAIDs may
cause direct harm on the progression of acute respiratory tract
infections including an increased risk of prolonged illness duration,
doctor reconsultations, and suppurative complications including
peritonsillar abscess (Basille 2017; Le Bourgeois 2016; Little 2013;
Little 2016; Nicollas 2020; Piroulas 2019; Voiriot 2011). As such, it
is important to systematically synthesise the available evidence on
the clinical benefit and adverse events of NSAIDs for sore throat in
children and adults.
O B J E C T I V E S
To assess the eFects of non-steroidal anti-inflammatory drugs
(NSAIDs) for acute sore throat in children and adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include both individually randomised controlled trials
(RCTs), that is where the participant is the unit of randomisation,
and cluster-RCTs. In addition, we will include the following types
of studies for the primary adverse event outcome 'infection-
related adverse events, defined as reconsultation rates with the
same symptoms (sore throat) or progressive/new symptoms, and/
or complications (e.g. peritonsillar abscess) within one month':
quasi-RCT (Q-RCT), non-RCT (NRCT), prospective cohort study,
and retrospective cohort study. We aim to include these types
of observational studies for our  primary adverse event outcome
since  RCTs are usually underpowered to identify potentially
important diFerences in the occurrence of rare complications
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between treatment groups;  this approach might therefore allow
us to more carefully weigh benefits and harms of NSAIDs use in
patients with acute sore throat.
We will include studies irrespective of publication status, date of
publication, or language.
Types of participants
We will include both children and adults presenting in a
primary healthcare setting (i.e. patients who are not referred
by a physician because of the current sore throat episode, or
patients presenting through self-referral in ambulatory care or
an emergency department) with sore throat. We will include the
following conditions:
1. clinical signs and symptoms suggestive of acute tonsillitis -
inflammation of the tonsils;
2. clinical signs and symptoms suggestive of pharyngitis -
inflammation of the oropharynx; and
3. clinical syndrome of sore throat (painful throat, odynophagia).
We will exclude studies of referred patients, hospitalised patients,
as well as those involving highly specialised populations (e.g. those
with glandular fever, immunodeficiency, peritonsillar abscess, or
sore throat following tonsillectomy).
Types of interventions
We will include studies irrespective of the dose, duration, or
method of administration of NSAIDs.
We will include trials comparing:
1. NSAIDs with placebo;
2. NSAIDs with no treatment;
3. NSAIDs with paracetamol (acetaminophen);
4. NSAID  and paracetamol (acetaminophen) with placebo and
paracetamol (acetaminophen);
5. NSAIDs and paracetamol  (acetaminophen) with
paracetamol (acetaminophen) alone;
6. NSAIDs with other pharmacological treatments such as lozenges
(not containing NSAIDs) and herbal medicinal products; and
7. NSAIDs with non-pharmacological treatments such as physical
cooling (e.g. ice cubes, wet cloths) and topical treatments (e.g.
gargling with povidone-iodine or salt).
We will include trials reporting combined interventions if they allow
a direct comparison between the NSAID and control groups (e.g. co-
administration of antibiotics in both groups). We will address the
following comparison pairs separately:
1. NSAIDs and antibiotics versus placebo and antibiotics; and
2. NSAIDs and antibiotics versus antibiotics alone.
Types of outcome measures
We will analyse the following outcomes in the review, but will not
use them as a basis for including or excluding studies.
Primary outcomes
1. Complete resolution of pain at two to three days (48 to 72 hours;
when symptoms are usually worst).
2. Infection-related adverse events, defined as reconsultation
with the same symptoms (sore throat) or progressive/new
symptoms, and/or complications (e.g. peritonsillar abscess)
within one month.
Secondary outcomes
1. Disease-specific quality of life using a validated instrument.
2. Complete resolution of pain at very short periods of time (1 hour,
2 to 3 hours, 4 to 6 hours).
3. Complete resolution of pain at various other time points (24
hours, 4 to 7 days).
4. Mean time to complete resolution of pain.
5. Pain intensity at various time points (1 hour, 2 to 3 hours, 4 to 6
hours, 24 hours, 2 to 3 days, and 4 to 7 days).
6. Mean time to resolution of fever.
7. Mean time to complete resolution of total symptoms (recovery).
8. Mean time to return to a normal diet.
9. Sore throat recurrences aOer one month.
10.Adverse eFects likely to be related to the  use of NSAIDs: i)
proportion of participants with gastrointestinal (GI) complaints
(excluding GI bleeding); and ii) proportion of participants
with GI bleeding, and/or renal failure, and/or cardiovascular
diseases (myocardial infarction; transient ischaemic attack;
cerebrovascular accident).
Search methods for identification of studies
We will conduct systematic searches for RCTs and controlled clinical
trials. We will perform a separate search for non-randomised
studies reporting on infection-related adverse events, using
established filters to identify reports of adverse events. We will
attempt to identify all relevant studies regardless of language or
publication status (published, unpublished, in press, ongoing).
Electronic searches
We will search the following databases from inception to present,
using the search terms and strategy described in Appendix 1:
1. Cochrane Central Register of Controlled Trials (CENTRAL),
published in the Cochrane Library;
2. MEDLINE (Ovid);
3. Embase (Ovid); and
4. CINAHL (Cumulative Index to Nursing and Allied Health
Literature) (EBSCOHost).
We will also search the World Health Organization (WHO)
International Clinical Trials Registry Platform (www.who.int/ictrp/
en/) and US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (clinicaltrials.gov) for trials in progress. We will
also run searches of Google Scholar using the same terms to
retrieve grey literature and other trials. We will report all search
details in the final version of the review.
Searching other resources
We may contact original authors for clarification and further data
if trial reports are unclear. We will arrange translations of papers
where necessary.
We will also check the reference lists of all included studies and
those of relevant review articles identified by the searches.
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Data collection and analysis
Selection of studies
Two  review authors (RPV, RTvU) will independently screen titles
and abstracts of the records obtained from the searches. We will
first identify and exclude duplicates, and then screen the titles
and abstracts of the unique records to identify potentially relevant
studies. We will retrieve the full-text study reports/publications of
all potentially eligible studies. The same two review authors will
independently review the full texts against the predefined inclusion
and exclusion criteria for eligibility. Any disagreements will be
resolved through discussion or by consulting a third review author
(PL) if required.
We will collate multiple reports of the same study so that each
study, rather than each report, is the unit of interest in the review.
We will record the selection process in suFicient detail to complete
a PRISMA flow diagram and 'Characteristics of excluded studies'
table (Moher 2009).
Data extraction and management
We will use a data collection form for the extraction of study
characteristics and outcome data that has been piloted on at
least one study in the review. Two review authors (RPV, RTvU) will
independently extract the following study characteristics from the
included studies:
1. methods: study design, total duration of study, details of any
'run-in' period, number of study centres and location, study
setting, withdrawals, and date of study;
2. participants: number, mean age, age range, gender, severity of
condition, diagnostic criteria, inclusion criteria, and exclusion
criteria;
3. interventions: intervention (including instruction about NSAIDs
use and NSAID type), comparison, concomitant medications,
and excluded medications;
4. outcomes: primary and secondary outcomes specified and
collected, and time points reported; and
5. notes: funding for trial, and notable conflicts of interest of trial
authors.
Two review authors (RPV, RTvU) will independently extract
outcome data from the included studies. We will note in
the 'Characteristics of included studies' table (see Table 1 for
template) if outcome data are not reported in a useable way. Any
disagreements will be resolved by consensus or by involving a third
review author (PL). One review author (RPV) will transfer data into
the Review Manager file using RevMan Web (RevMan Web 2019). We
will double-check that data are entered correctly by comparing the
data presented in the systematic review with the study reports. A
second review author (RTvU) will spot-check study characteristics
for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (RPV, RTvU) will independently assess risk of
bias for the included RCTs using the Cochrane 'Risk of bias' tool for
randomised trials (RoB 2) (Sterne 2019), according to the guidance
in the latest version of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2019). Any disagreements will be
resolved by discussion or by involving another review author (PL).
We will assess risk of bias as 'low', 'high', or 'some concerns' for each
of the following five domains:
1. bias arising from the randomisation process;
2. bias due to deviations from the intended interventions;
3. bias due to missing outcome data;
4. bias in measurement of outcome; and
5. bias in selection of the reported results.
For cluster-RCTs, we will assess risk of bias using these five domains
in addition to a sixth domain described in the latest version of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2019), namely "Bias arising from the timing of identification and
recruitment of participants".
We will provide a quote from the study report together with a
justification for our judgement in the 'Risk of bias' table. We will
summarise the 'Risk of bias' judgements across diFerent studies
for each of the domains listed. Where information on risk of bias
relates to unpublished data or correspondence with an individual
trial author, we will note this in the 'Risk of bias' table.
We will manage the risk of bias through the MicrosoO Excel tool
available at  www.riskofbias.info  (Sterne 2019).  For assessment
of the overall risk of bias, we will use signalling questions and
algorithm tools (Higgins 2019). We will assess risk of bias of the RCTs
using the RoB 2 tool based on the following outcomes:
1. complete resolution of pain at two to three days (48 to 72 hours;
when symptoms are usually worst);
2. infection-related adverse events, defined as reconsultation
with the same symptoms (sore throat) or progressive/new
symptoms, and/or complications (e.g. peritonsillar abscess)
within one month;
3. complete resolution of pain at various other time points (24
hours, four to seven days);
4. mean time to resolution of fever;
5. mean time to complete resolution of total symptoms (recovery);
6. mean time to return to normal diet; and
7. adverse eFects likely to be related to the use of NSAIDs.
We will store the consensus decisions for the signalling questions
as supplemental data.
The eFect of interest will be  ‘eFect of assignment’ (intention-to-
treat (ITT) principle).
We will assess risk of bias for relevant non-randomised
studies using the ROBINS-I tool (Sterne 2016). We will use this tool
to assess the risk of bias of the primary adverse event outcome
'infection-related adverse events, defined as reconsultation rates
with the same symptoms (sore throat) or progressive/new
symptoms, and/or complications (e.g. peritonsillar abscess) within
one month'. We will assess the following confounders:  age,
comorbidity, aetiology, fever, symptom severity, prior duration of
symptoms, exudate, severe inflammation of the pharynx, and co-
treatment with antibiotics.
Non-steroidal anti-inflammatory drugs (NSAIDs) for acute sore throat (Protocol)
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Assessment of bias in conducting the systematic review
We will conduct the review according to this published protocol and
report any deviations from it in the 'DiFerences between protocol
and review' section of the systematic review.
Measures of treatment e9ect
We will enter the outcome data for each study into the data tables in
RevMan Web to calculate the treatment eFects (RevMan Web 2019).
We will use risk ratios (RR) with 95% confidence intervals (CIs) for
dichotomous outcomes and mean diFerences (MD) with standard
deviations (SD) or as standardised mean diFerences (SMD) for
continuous outcomes. Where SMD has been computed, we will re-
express the outcomes in a single natural scale (to be determined
based on the scales from the observed studies).
For each of the key outcomes listed in the 'Summary of findings'
table, we  will  present  the results for the  absolute numbers (in
addition to the relative numbers) based on the pooled results and
compared to the assumed risk. Where applicable, we will also
calculate the number needed to treat for an additional beneficial
outcome (NNTB) and number needed to treat for an additional
harmful outcome (NNTH) using the pooled results.
Unit of analysis issues
For cluster-RCTs, we will consider potential diFerences between the
intervention eFects being estimated and check whether clustering
was taken into account in the analysis of the individual trials.
Additionally, as per the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2019), we will report on whether or not
the sample sizes were estimated through the intracluster/intraclass
correlation coeFicient (ICC) and whether the analyses were carried
out at the cluster level. Where trials take multiple measurements
or observations of a single outcome in the same participants
(repeated measurements), we will only extract and analyse the
datapoints consistent with the times of follow-up defined in the
primary and secondary outcomes in this protocol.
Dealing with missing data
We will contact individual trial authors or study sponsors to verify
key study characteristics and to obtain missing numerical outcome
data where possible (e.g. when a study is identified as abstract
only). Where this is not possible, and the missing data are thought
to introduce serious bias, we will explore the impact of including
such studies in the overall assessment of results by a sensitivity
analysis, provided suFicient data are available.
If SDs are missing and they cannot be obtained from the trial
authors, we will approximate them using other available statistics
such as P values or alternative methods according to the methods
described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2019).
Apart from imputations for missing SDs, we will not conduct any
other imputations. We will extract and analyse all data using the
available-case analysis method  based on the ITT  principle,  that
is by analysing all participants in the groups to which they had
originally been randomised.
Assessment of heterogeneity
We will assess clinical heterogeneity by reviewing the included
trials for potential diFerences between trials in study populations,
interventions or comparisons used, and outcomes measured.
We will assess statistical heterogeneity for each outcome by visually
inspecting the forest plots and by using the I2 statistic, with
investigation of I2 values over the ranges described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2019).
Assessment of reporting biases
To assess outcome reporting bias, we will search the internet and
ClinicalTrials.gov (clinicaltrials.gov) for available study protocols to
determine whether the outcomes reported in the included trials
were predefined and whether all outcomes listed in the study
protocol are reported in the publication. We propose that if there
are suFicient trials, we will assess reporting bias by using funnel
plots. If we are able to pool more than 10 trials, we will create
and examine a funnel plot to explore possible small-study and
publication biases.
Data synthesis
We will analyse the data according to the ITT principle. Where data
are missing or there was loss to follow-up, we will conduct an
available-case analysis.
We will pool data from studies we judge to be clinically
homogeneous using RevMan Web (RevMan Web 2019). If more than
one study provides useable data in any single comparison, we
will perform a meta-analysis using a random-eFects (DerSimonian
and Laird) model to provide a more conservative estimate. We will
include all eligible studies in the primary analyses, but we will
perform separate meta-analyses for RCTs and non-RCTs (for the
primary adverse event outcome).
For non-RCTs, our primary analyses will include eligible studies
where the  data have  been adjusted (with common criteria).
Secondary analyses will consist of combining eligible studies where
the data have not been adjusted. We will discuss the limitations of
these analyses in both cases.
Subgroup analysis and investigation of heterogeneity
We will perform subgroup analyses planned a priori for the
following characteristics if there are at least 10 studies available for
each subgroup stratum:
1. age (children versus adults);
2. Centor criteria (0 to 2 versus 3 to 4);
3. prior duration (three days or less versus over three days);
4. fever (body temperature > 38 °C present versus absent);
5. NSAID type (sprays versus lozenges versus tablets/capsules/
suppositories/injections); and
6. instruction about NSAIDs use (at regular time intervals versus as
needed).
We will use the Chi2 test to test for subgroup interactions in Review
Manager (RevMan Web 2019).
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Sensitivity analysis
We plan to carry out sensitivity analyses to determine the
robustness of our 'Risk of bias' findings for the included studies by
excluding studies with high risk of overall bias for the results as
assessed using the Cochrane RoB 2 tool (Higgins 2019).
Summary of findings and assessment of the certainty of the
evidence
We will create a 'Summary of findings' table using the following
seven top-priority outcomes:
1. complete resolution of pain at two to three days (48 to 72 hours;
when symptoms are usually worst);
2. infection-related adverse events, defined as reconsultation
with the same symptoms (sore throat) or progressive/new
symptoms, and/or complications (e.g. peritonsillar abscess)
within one month;
3. complete resolution of pain at various other time points (24
hours, four to seven days);
4. mean time to resolution of fever;
5. mean time to complete resolution of total symptoms (recovery);
6. mean time to return to normal diet; and
7. adverse eFects likely to be related to the use of NSAIDs.
We will use the five GRADE considerations (study limitations,
inconsistency, imprecision, indirectness, and publication bias) to
rate the overall certainty of the evidence for each outcome (Atkins
2004). We will use the methods and recommendations described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2019), employing GRADEpro GDT soOware (GRADEpro
GDT). We will justify all decisions to down- or upgrade the certainty
of the evidence using footnotes, and will make comments to aid the
reader's understanding of the review where necessary.
A C K N O W L E D G E M E N T S
The methods section of this protocol is based on a standard
template developed by the Cochrane Airways Group and adapted
by the Cochrane Acute Respiratory Infections Group. We wish to
thank the following people for commenting on the draO protocol:
Amanda Roberts, Ann Fonfa, Mark Ebell, Anneliese Spinks, Robert
Ware, and Johannes C van der Wouden.
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A D D I T I O N A L   T A B L E S
 
Methods Study design (e.g. parallel RCT, cross-over RCT, cluster-RCT)
Study duration: date of first recruitment to last follow-up
Participants Inclusion criteria
Setting: e.g. outpatient, inpatient, multicentre, national/international
Country: list all countries
Relevant health status:
Number: treatment (N = x); control (N = x)
Age (mean, SD/median, range)
Treatment group:
Table 1.   'Characteristics of included studies' table template 
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Control group:
Sex (M/F): treatment (N/N M/F); control (N/N M/F)





Dose, duration, frequency, administration
Other relevant info
Control group
Intervention (e.g. placebo, no treatment)






Note: describe the methods used to measure the outcomes
Notes Declaration of Interest:
Funding source:
Contact with study authors for additional information:
Other:
Table 1.   'Characteristics of included studies' table template  (Continued)
 
 
A P P E N D I C E S
Appendix 1. Detailed search strategy
Ovid MEDLINE® and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions® 1946 to present








9 (tonsil* adj2 (inflam* or infect*)).mp.
10 ((throat* or pharyn*) adj3 (infect* or inflam*)).mp.
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
12 Anti-Inflammatory Agents, Non-Steroidal/ or non-steroidal antiinflammatory agent*.mp.
13 NSAID*.mp.
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14 ((non-steroid* or nonsteroid* or non steroid*) and (anti-inflammator* or antiinflammator* or anti inflammator*)).mp.
15 apazone.mp. or Apazone/
16 aspirin.mp. or Aspirin/
17 celecoxib.mp. or Celecoxib/
18 diclofenac.mp. or Diclofenac/
19 diflunisal.mp. or Diflunisal/
20 etodolac.mp. or Etodolac/
21 fenoprofen.mp. or Fenoprofen/
22 flurbiprofen.mp. or Flurbiprofen/
23 ibuprofen.mp. or Ibuprofen/
24 indomethacin.mp. or Indomethacin/
25 ketoprofen.mp. or Ketoprofen/
26 Ketorolac/ or Ketorolac Tromethamine/ or ketorolac.mp.
27 Meclofenamic Acid.mp. or Meclofenamic Acid/
28 meclofenamate.mp.
29 meloxicam.mp. or Meloxicam/
30 (methyl salicylate or methylsalicylate).mp
31 nabumetone.mp. or Nabumetone/
32 naproxen.mp. or Naproxen/
33 nimesulide.mp.
34 oxaprozin.mp. or Oxaprozin/
35 phenylbutazone.mp. or Phenylbutazone/
36 piroxicam.mp. or Piroxicam/
37 salicylate.mp. or Salicylates/
38 sulindac.mp. or Sulindac/
39 tenoxicam.mp.
40 tolmetin.mp. or Tolmetin/
41 tiaprofenic acid.mp.
42 niflumic acid.mp. or Niflumic Acid/
43 acetylsalicyclic acid.mp.
44 morniflumate.mp.
45 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35
or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44
46 11 and 45
This is the search strategy for MEDLINE (OVID). We will combine it with the Cochrane Highly Sensitive Search Strategy for randomised trials:
sensitivity and precision-maximising version (2008 revision) (Lefebvre 2019), to identify reports of randomised controlled trials.
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We will combine this search strategy with the Canadian Agency for Drugs and Technologies in Health (CADTH): MEDLINE adverse eFects
filter and/or with the BMJ Clinical Evidence: MEDLINE adverse eFects strategy (both reported in Farrah et al 2016), to identify non-
randomized reports of adverse events.
The MEDLINE (OVID) strategy will be modified as needed for other electronic databases. All search strategies will be reported in the final
version of the review.
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